With more than 30 years of experience in developing tactile and sensory measurement technologies, Jun Wada founded Hapquitous in 2023 upon turning 60. Guided by the mission of “bringing the potential of sensation and perception to anyone, anywhere,” Hapquitous developed Pain Compass®, a novel device based on the Thermal Grill Illusion (TGI). The system provides a three-minute assessment that objectively evaluates stress-related hypersensitivity in the brain and visualizes presenteeism—conditions that typically remain hidden in the workplace. Hapquitous offers an integrated solution that connects measurement → intervention (acupuncture, exercise, psychological support) → follow-up assessment, enabling early detection and improvement of employee well-being. Hapquitous is currently conducting collaborative research with ten institutions, including Kyoto Tachibana University, Kio University, and the University of Tokyo School of Medicine.
A startup that synthesizes long, complex DNA using proprietary technology, enabling the flexible design of diverse gene combinations. It also provides comprehensive support from development to manufacturing processes for viral vectors and mRNA required for gene therapy.
① Research and development of brain stimulation therapy devices. ② Development and sales of medical and healthcare applications.
Development of small-molecule therapeutics targeting RNA.
A biotech startup developing T-cell and NK-cell therapies derived from low-immunogenicity iPS cells. It aims to provide new treatments for solid tumors and autoimmune diseases, contributing to the treatment of previously difficult-to-treat intractable diseases.